Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Barcelona, Spain – 27 Aug 2017: Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with stable coronary or peripheral artery disease, according to late-breaking results from the COMPASS trial presented today in a Hot Line-LBCT Session at ESC Congress (1) and published in the NEJM.
One-third of the 55 million deaths in the world each year are from cardiovascular causes. Patients with known coronary or peripheral artery disease are at risk of death, stroke and heart attack. Aspirin is the single most widely used treatment to prevent strokes and heart attacks but is only modestly effective.
The COMPASS trial (2) tested two possible ways to improve on aspirin, by using the combination of rivaroxaban and aspirin, or by using rivaroxaban alone, to protect against heart attack and stroke in patients with stable coronary or peripheral artery disease.
The trial randomised 27 395 patients from 33 countries in North America, South America, Asia, Western Europe, Eastern Europe, South Africa and Australia. The treatments tested were rivaroxaban 2.5mg twice daily plus aspirin 100mg once daily and rivaroxaban 5mg twice daily, each of which were compared to standard therapy with aspirin 100mg once daily. The primary endpoint was a composite of cardiovascular death, stroke or myocardial infarction.
On 6 February 2017 the Data Safety Monitoring Board recommended that the rivaroxaban and aspirin arms be stopped because of a clear superiority of the combination of rivaroxaban and aspirin over aspirin alone.
The results indicate that the addition of rivaroxaban to aspirin, compared with aspirin alone, reduced cardiovascular death, stroke, or heart attack by 24%, and improved survival by 18%. Rivaroxaban 5mg twice daily was not superior to aspirin alone. The addition of rivaroxaban to aspirin increased bleeding, and the most common site of bleeding was in the stomach or lower bowel. There was no significant increase in fatal or brain bleeding.
Dr John Eikelboom, co-principal investigator and associate professor, McMaster University, Hamilton, Canada, said: “The substantial benefits seen with rivaroxaban and aspirin support the approach of using low doses of the two treatments in combination. Recent trials in other disease areas have demonstrated substantial benefits from using low doses of a combination of drugs and this concept is now further supported by the results of COMPASS.”
Prof Stuart Connolly, co-principal investigator and professor of medicine at McMaster University, suggested that the increase in bleeding should be considered in the context of the overall findings. He said: “Many of these bleeds were not serious and despite the increase in bleeding the results clearly show a net benefit for patients, as highlighted by the 18% reduction in mortality.”
The data indicates that for every 1 000 patients treated for an average of 23 months, rivaroxaban plus aspirin prevents 13 heart attacks, strokes, or cardiovascular deaths, and seven deaths from any cause, at a cost of 12 major bleeds, most of which were readily treatable. The benefits of the drug combination were achieved in patients in whom lipid-lowering and blood pressure-lowering drugs, and angiotensin converting enzyme (ACE) inhibitors were widely used.
“It is noteworthy that the benefits of the combination of rivaroxaban and aspirin are on top of proven therapies,” said Prof Salim Yusuf, chair of the COMPASS Steering Committee and director of the Population Health Research Institute at McMaster University. “If rivaroxaban plus aspirin is widely adopted, the potential benefits are enormous. Use of the combination in 10% of the approximately 300 million persons around the world with known cardiovascular disease would prevent as many as 100 000 deaths and twice as many premature vascular events each year.”
Sources of funding: The COMPASS trial was sponsored by Bayer AG.
Disclosures: Dr Eikelboom and Prof Connolly have received consulting fees and/or honoraria and grant and/or in-kind support from Astra-Zeneca, Bayer Boehringer-Ingelheim, Bristol-Myer-Squibb, Daiichi-Sankyo, Eli-Lilly, Glaxo-Smith-Kline, Pfizer, Janssen, Sanofi-Aventis. Dr Yusuf has received research grants, honoraria and travel expenses for lectures from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, and Astra Zeneca.
References and notes:(1) The study “Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial: Primary Results” will be presented during:• The press conference Hot Line - Late Breaking Clinical Trials 1 on Sunday 27 August from 8:00 to 9:00.• The session Hot Line - Late Breaking Clinical Trials 1 on Sunday 27 August from 11:00 to 12:30 in Barcelona – Main Auditorium.(2) The COMPASS (Cardiovascular OutcoMes for People using Anticoagulation StrategieS) trial was conducted in 602 centres in 33 countries, and is coordinated by the Population Health Research Institute, Hamilton Health Sciences and McMaster University.
ESC Press OfficeFor more information, please contact the ESC Press Office: email@example.com.For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856The press conference timetable is available here.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. About the European Society of CardiologyThe European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.About ESC Congress 2017ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at firstname.lastname@example.org.This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our Mission: To Reduce the Burden of Cardiovascular Disease
© 2019 European Society of Cardiology. All rights reserved